Published in J Acquir Immune Defic Syndr on December 07, 2016
A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people. BMC Psychiatry (2008) 5.82
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA (2014) 4.49
Factors influencing the development and amelioration of suicidal thoughts in the general population. Cohort study. Br J Psychiatry (2004) 2.95
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis (2013) 2.65
Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry (2009) 2.12
HIV and depression: 2008 review and update. Curr HIV/AIDS Rep (2008) 2.08
Limitations and strengths of spontaneous reports data. Clin Ther (1998) 1.84
Suicidal risk factors and completed suicide: meta-analyses based on psychological autopsy studies. Environ Health Prev Med (2008) 1.78
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV (2015) 1.70
Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med (2005) 1.45
High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.38
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr (2015) 1.28
A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav (2011) 1.28
Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Int J Nurs Stud (2014) 1.25
Differentiating nonrestorative sleep from nocturnal insomnia symptoms: demographic, clinical, inflammatory, and functional correlates. Sleep (2013) 1.21
HIV infection and mental health: suicidal behaviour--systematic review. Psychol Health Med (2011) 1.20
Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci (2005) 1.12
HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother (2015) 1.02
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials (2014) 0.99
Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs (2014) 0.92
Long-term safety from the raltegravir clinical development program. Curr HIV Res (2011) 0.91
Associations of allostatic load with sleep apnea, insomnia, short sleep duration, and other sleep disturbances: findings from the National Health and Nutrition Examination Survey 2005 to 2008. Ann Epidemiol (2014) 0.89
Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS (2008) 0.87
AIDS/HIV infection, comorbid psychiatric illness, and risk for subsequent suicide: a nationwide register linkage study. J Clin Psychiatry (2012) 0.86
Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther (2015) 0.83
Role of raltegravir in HIV-1 management. Ann Pharmacother (2012) 0.80
Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf (2014) 0.77
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis (2009) 3.44
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr (2010) 2.85
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog (2009) 2.06
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61
Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr (2009) 1.56
A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data. Pharmacoepidemiol Drug Saf (2013) 1.48
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. AIDS (2013) 1.40
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Host determinants of antiretroviral drug activity. Curr Opin Infect Dis (2005) 1.16
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open (2011) 1.15
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS (2007) 1.13
Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials (2011) 1.11
Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection. Clin Vaccine Immunol (2009) 1.05
Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS (2014) 1.04
HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis (2004) 1.03
Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis (2003) 1.01
Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials (2007) 1.01
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther (2014) 0.99
Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs (2009) 0.97
Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study. Sex Transm Infect (2013) 0.97
High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J Acquir Immune Defic Syndr (2010) 0.95
Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?. AIDS (2015) 0.92
Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect (2012) 0.92
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antivir Ther (2010) 0.92
Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS One (2012) 0.90
Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS (2009) 0.90
Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. Breast Cancer Res (2004) 0.90
Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy. AIDS Res Hum Retroviruses (2009) 0.90
Pharyngeal gonorrhoea - is dual therapy the way forward? Int J STD AIDS (2007) 0.88
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
HIV, dementia and antiretroviral drugs: 30 years of an epidemic. J Neurol Neurosurg Psychiatry (2013) 0.86
The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Curr Med Res Opin (2010) 0.85
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother (2011) 0.85
Raltegravir: a new choice in HIV and new chances for research. Lancet (2009) 0.84
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. J Antimicrob Chemother (2013) 0.83
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data. Pediatr Infect Dis J (2014) 0.83
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. Pediatr Infect Dis J (2014) 0.82
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother (2009) 0.82
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients. AIDS Res Hum Retroviruses (2008) 0.81
Truncated robust distance for clinical laboratory safety data monitoring and assessment. J Biopharm Stat (2012) 0.80
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopy. HIV Clin Trials (2012) 0.80
An unusual abacavir reaction. AIDS (2008) 0.80
Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother (2010) 0.80
The clinical implications of antiretroviral pharmacogenomics. Pharmacogenomics (2006) 0.80
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study. HIV Clin Trials (2007) 0.79
Etravirine plasma levels in a patient with decompensated liver disease. AIDS (2009) 0.78
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. J Acquir Immune Defic Syndr (2006) 0.77
HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient subgroups. Antivir Ther (2013) 0.77
Combining resistance and pharmacology for optimum patient care. Curr Opin HIV AIDS (2007) 0.77
Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy. AIDS (2003) 0.76
Atherosclerosis is Evident in Treated HIV-Infected Subjects With Low Cardiovascular Risk by Carotid Cardiovascular Magnetic Resonance. J Acquir Immune Defic Syndr (2016) 0.76
Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment". J Acquir Immune Defic Syndr (2007) 0.75
High treatment success rates when switching to once daily nevirapine containing antiretroviral therapy. Open AIDS J (2008) 0.75
Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701. Clin Infect Dis (2007) 0.75
The feasibility of creating a population-based national twin registry in the United States. Twin Res Hum Genet (2006) 0.75
Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients. HIV Clin Trials (2013) 0.75
The K65R mutation in HIV-1 reverse transcriptase. J HIV Ther (2004) 0.75
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV Clin Trials (2015) 0.75
Venous and arterial blood lactate in HIV-infected patients. Antivir Ther (2002) 0.75
The rationale and development of new drugs to treat HIV infection. Med Chem (2005) 0.75
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen. J Acquir Immune Defic Syndr (2006) 0.75
Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues. AIDS Res Hum Retroviruses (2011) 0.75
Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? AIDS (2007) 0.75
Measurement of retinal vessels as a biomarker of cerebrovascular ageing in older HIV positive men compared to controls. J Acquir Immune Defic Syndr (2017) 0.75
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. J Acquir Immune Defic Syndr (2009) 0.75
Measuring and managing cognitive impairment in HIV. AIDS (2017) 0.75
Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls. HIV Clin Trials (2015) 0.75